{"news_desk": "Business", "print_page": "2", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"contributor": "Andrew Pollack contributed reporting.", "original": "By MATTHEW GOLDSTEIN", "person": [{"rank": 1, "role": "reported", "firstname": "Matthew", "organization": "", "lastname": "GOLDSTEIN"}]}, "abstract": "Turing Pharmaceuticals founder Martin Shkreli is served subpoena to appear before House Committee on Oversight and Government Reform to discuss pricing trends and other developments in drug industry; it is unclear whether Shkreli, who has been charged with securities fraud, will show up to testify.", "type_of_material": "News", "word_count": "848", "lead_paragraph": "Mr. Shkreli, a former Turing chief executive who has been criticized over drug pricing, was called to appear for a hearing to discuss pricing trends.", "pub_date": "2016-01-21T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Congress Calls Martin Shkreli to Testify on Rapid Rises in Drug Pricing", "print_headline": "Congress Calls Shkreli to Testify on Rapid Rises in Drug Pricing"}, "snippet": "Mr. Shkreli, a former Turing chief executive who has been criticized over drug pricing, was called to appear for a hearing to discuss pricing trends.", "multimedia": [{"height": 126, "url": "images/2016/01/21/business/21Shkrelisub/21Shkrelisub-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2016/01/21/business/21Shkrelisub/21Shkrelisub-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 447, "url": "images/2016/01/21/business/21Shkrelisub/21Shkrelisub-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "447", "xlarge": "images/2016/01/21/business/21Shkrelisub/21Shkrelisub-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2016/01/21/business/21Shkrelisub/21Shkrelisub-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2016/01/21/business/21Shkrelisub/21Shkrelisub-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2016/01/21/business/dealbook/congress-subpoenas-martin-shkreli-over-drug-prices.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Turing Pharmaceuticals AG", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "Shkreli, Martin (1983- )", "name": "persons"}, {"rank": "3", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "House Committee on Oversight and Government Reform", "name": "organizations"}, {"rank": "5", "is_major": "N", "value": "Prices (Fares, Fees and Rates)", "name": "subject"}, {"rank": "6", "is_major": "N", "value": "Securities and Commodities Violations", "name": "subject"}], "blog": [], "_id": "569fe66a38f0d80627b20ab9", "source": "The New York Times"}